Screener
Cumberland Pharmaceuticals CPIX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Acetadote | $136.66K-29.4% | $51.98K-65.7% | $66.67K+65.8% | $96.6K+352% | $193.54K+346% | |
| Caldolor | $1.47M-7.2% | $965.56K-26.1% | $896.71K-34.7% | $867.01K-31.8% | $1.59M+88.1% | |
| Kristalose | $1.06M-61.5% | $981.48K-71.8% | $3.12M-28.7% | $1.18M-67.5% | $2.75M-33.0% | |
| Other revenue | $221.53K-55.0% | $168.85K-94.6% | $184.62K-14.9% | $306.51K-50.9% | $492.39K+130% | |
| Sancuso | $1.82M-41.8% | $2.93M+29.8% | $3.29M+38.2% | $3.24M+24.3% | $3.12M+42.5% | |
| Talicia | $2.35M— | $1.92M— | —— | —— | $0— | |
| Vibativ | $1.74M-35.6% | $2.12M-29.4% | $2.81M+35.4% | $2.6M+153% | $2.7M+10.1% |
FAQ
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
